In vivo analysis reveals metabolism rates of β-isomers in humans, suggesting 2-propoxypropanoic acid as a biomarker.
Propylene glycol ethers (PGEs) consist of a major α-isomer (secondary alcohol group) and a minor β-isomer (primary alcohol group). Animal studies have reported toxic effects of the β-isomer metabolites, but human metabolism of PGEs remains poorly understood. We aimed to characterize the metabolism of two common PGEs in humans. Nine participants were exposed under controlled conditions (4h) to propylene glycol ethyl ether (PGEE) or propylene glycol propyl ether (PGPE) (<35 ppm). Blood and urine samples were collected, and the respective β-isomers metabolites; 2-ethoxypropanoic acid (2-EPA) and 2-propoxypropanoic acid (2-PPA) were quantified. The 2-PPA blood absorption rate was 0.0005 ±0.0002µg/mL/h*ppm followed by rapid urinary elimination (half-life: 2h) and slower secondary elimination (half-life: 10h). No dose-response was observed for 2-EPA; therefore, β-PGEE metabolism was investigated in vitro using human liver S9 fractions. We provide 2-EPA hepatic kinetic and enzyme kinetic parameters. We recommend using of 2-PPA as a biomarker for PGPE exposures.
No takes yet. Share an insight, caveat, or question.
Luca et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: